Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trial Completed
609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies